Navigation Links
Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
Date:5/5/2011

German researchers have identified an unexpected molecular marker that predicts how sensitive hard-to-treat triple-negative breast cancers are to chemotherapy.

Triple-negative breast cancers --which do not express the genes for estrogen receptor, or progesterone receptor and do not have Her2/neu overexpression or amplification-- are more aggressive than other forms of the disease and cannot be treated with endocrine or Her2 targeted therapies.

At the IMPAKT Breast Cancer Conference in Brussels, PhD student Carolin Huelsewig and Dr Cornelia Liedtke from Uniklinikum Muenster report that the molecule sFRP1 is much more highly expressed in these cancers, and that levels of the molecule in an individual tumor correlate with its sensitivity to chemotherapy.

The researchers undertook their study in three steps. First they conducted a gene expression analysis in breast cancer tissue samples, looking specifically for genes whose expression level differed between triple-negative cancers and non-triple negative cancers.

That analysis revealed that sFRP1 was the most highly overexpressed gene in triple-negative cancers relative to others. "The degree of difference was up to 4.7-fold in triple-negative vs. non-triple negative cancers," Ms Huelsewig said.

The results were a surprise, as sFRP1 is known to inhibit a signaling pathway within cells that is associated with the development of cancers. "The results of the differential gene expression analysis were initially astounding as sFRP1 has so far been understood as an antagonist within the wnt signaling cascade."

The researchers then tested genes for an association with relapse-free survival and response to neoadjuvant chemotherapy, finding that while sFRP1 expression was not associated with recurrence-free survival, it was significantly correlated with an increased sensitivity to chemotherapy.

Finally, the researchers conducted 'knockdown' experiments in cell culture, using the triple-negative breast cancer cell line MDA-MB 468. These experiments involved using short segments of RNA, known as siRNA, designed to block the expression of sFRP1. In breast cancer cells where sFRP1 expression was knocked down, there was significantly decreased sensitivity to paclitaxel, doxorubicin and cisplatinum, they found.

"It is increasingly recognized that molecular subtypes of breast cancer may be examined and characterized individually --including the revealing of a potentially very distinct set of biomarkers and therapeutic tools. Our results suggest sFRP1 signaling as a biomarker tailored to the triple-negative breast cancer subtype," Ms Huelsewig said.

"It is important to recognize that our results are not ready to be transferred into the clinic just yet," she said. "However, our approach provides proof-of-principle that identification, validation and functional analysis of biomarkers for specific disease subtypes is feasible through translational research incorporating both in-silico analyses such as gene expression profiling and basic science including functional analyses."

Commenting on the study, which he was not involved in, Dr Stephen Johnston, from Royal Marsden NHS Foundation Trust & Institute of Cancer Research, highlighted that Triple Negative Breast Cancer (TNBC) is a sub-type that despite its response to chemotherapy, carries a bad prognosis.

"Understanding the molecular profile which drives this disease is crucial to allow us to use existing drugs better, as well as find more effective treatments. In both clinical and laboratory experiments these researchers have identified a gene called sFRP1 involved in the wnt signalling cascade that is frequently over-expressed in TNBC, and may predict who responds best to chemotherapy this could help select patients for treatment in the future."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Personal Tragedy Reveals Untapped Artistic Expression / Family Business Memorializes Loved Ones with Compassion During Grieving
2. Gene expression test reduces need for invasive heart muscle biopsy
3. Spanish gene expression data promise targeting of anti-angiogenesis treatment
4. “You Are Very Pretty”, Says Myeexpert As It Releases A Book, Poetic Expressions, Dedicated To The Beauty of Women.
5. Expression of certain transporter proteins may predict resistance to drug therapy
6. New genetic analysis reveals principles of phenotypic expression
7. Infants hemodynamic responses to happy and angry facial expressions
8. Attention ladies and gentlemen: Courtship affects gene expression
9. Overexpression of repetitive DNA sequences discovered in common tumor cells
10. Oncometabolite linked with widespread alterations in gene expression
11. Gene expression to distinguish metastasizing from non-metastasizing head and neck cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: